Related Experiment Video
Updated: Feb 3, 2026

Evaluating In Vitro DNA Damage Using Comet Assay
Published on: October 11, 2017
Selective cytotoxic activity and DNA damage by an epoxyalkyl galactopyranoside
Estefanía Burgos-Morón1, Nuria Pastor2, Manuel Luis Orta2
1Department of Pharmacology, Faculty of Pharmacy, University of Seville, Seville, Spain.
Abstract:
Preclinical Research & Development Several clinically useful anticancer drugs selectively kill cancer cells by inducing DNA damage; the genomic instability and DNA repair defects of cancer cells make them more vulnerable than normal cells to the cytotoxicity of DNA-damaging agents. Because epoxide-containing compounds can induce DNA damage, we have used the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to evaluate the selective cytotoxicity of three epoxyalkyl galactopyranosides against A549 lung cancer cells and MRC-5 lung normal cells. Compound (2S,3S)-2,3-epoxydecyl 4,6-O-(S)-benzylidene-β-d-galactopyranoside (EDBGP) showed the highest selective anticancer activity and was selected for mechanistic studies. After observing that EDBGP induced cellular DNA damage (comet assay), we found that cells deficient in nucleotide excision repair were hypersensitive to the cytotoxicity of this compound; this suggests that EDBGP may induce bulky DNA adducts. EDBGP did not inhibit glycolysis (glucose consumption and lactate production). Pretreatment of lung cancer cells with several antioxidants did not reduce the cytotoxicity of EDBGP, thereby indicating that reactive oxygen species do not participate in the anticancer activity of this compound. Finally, EDBGP was screened against a panel of cancer cells and normal cells from several tissues, including three genetically modified skin fibroblasts with increasing degree of malignancy. Our results suggest that epoxyalkyl galactopyranosides are promising lead compounds for the development of new anticancer agents.
Insights
Epoxyalkyl galactopyranosides show selective anticancer activity by inducing DNA damage in cancer cells. The compound EDBGP demonstrated potent efficacy, suggesting its potential as a novel anticancer drug lead.
Area of Science:
- Medicinal Chemistry
- Cancer Biology
- Drug Discovery
Background:
- DNA-damaging agents are effective anticancer drugs due to cancer cells' genomic instability and DNA repair defects.
- Epoxide-containing compounds can induce DNA damage, making them candidates for anticancer drug development.
Purpose of the Study:
- To evaluate the selective cytotoxicity of epoxyalkyl galactopyranosides against cancer cells.
- To investigate the mechanism of action of the most potent compound, EDBGP.
Main Methods:
- 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for cytotoxicity evaluation.
- Comet assay to detect DNA damage.
- Assessment of nucleotide excision repair deficiency, glycolysis, and reactive oxygen species involvement.
Main Results:
- Compound (2S,3S)-2,3-epoxydecyl 4,6-O-(S)-benzylidene-β-d-galactopyranoside (EDBGP) exhibited the highest selective anticancer activity.
- EDBGP induced DNA damage, and cells deficient in nucleotide excision repair were hypersensitive, suggesting bulky DNA adduct formation.
- EDBGP did not affect glycolysis or involve reactive oxygen species in its anticancer activity.
Conclusions:
- Epoxyalkyl galactopyranosides, particularly EDBGP, are promising lead compounds for developing new anticancer agents.
- EDBGP's mechanism involves inducing DNA damage, potentially through bulky adducts, and its efficacy is independent of glycolysis or reactive oxygen species.
Related Concept Videos
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
DNA Helicases
What is Natural Selection?
Overview of DNA Repair
Chemically...

